• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    10 Health Care Stocks With Whale Alerts In Today's Session

    5/5/22 1:48:15 PM ET
    $AXNX
    $CERN
    $CI
    $DOCS
    Medical/Dental Instruments
    Health Care
    Managed Health Care
    Health Care
    Get the next $AXNX alert in real time by email

    This whale alert can help traders discover the next big trading opportunities.

    Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.

    Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels.

    Here's the list of options activity happening in today's session:

    Symbol PUT/CALL Trade Type Sentiment Exp. Date Strike Price Total Trade Price Open Interest Volume
    RCUS PUT TRADE BULLISH 05/20/22 $30.00 $400.0K 2.0K 2.0K
    CERN CALL TRADE NEUTRAL 01/20/23 $90.00 $277.7K 9.9K 550
    AXNX PUT SWEEP BEARISH 06/17/22 $45.00 $25.8K 0 379
    PFE CALL TRADE NEUTRAL 01/20/23 $50.00 $46.8K 20.2K 360
    UNH PUT TRADE NEUTRAL 06/17/22 $500.00 $25.4K 1.1K 313
    MRNA PUT SWEEP BULLISH 05/13/22 $143.00 $71.4K 46 102
    DOCS PUT TRADE BULLISH 12/16/22 $45.00 $30.4K 683 69
    THC PUT TRADE BULLISH 06/17/22 $75.00 $50.9K 206 40
    SWAV CALL SWEEP BEARISH 05/20/22 $150.00 $27.9K 207 38
    CI CALL TRADE BULLISH 01/20/23 $200.00 $62.0K 26.1K 36

    Explanation

    These bullet-by-bullet explanations have been constructed using the accompanying table.

    • Regarding RCUS (NYSE:RCUS), we observe a put option trade with bullish sentiment. It expires in 15 day(s) on May 20, 2022. Parties traded 500 contract(s) at a $30.00 strike. The total cost received by the writing party (or parties) was $400.0K, with a price of $800.0 per contract. There were 2065 open contracts at this strike prior to today, and today 2010 contract(s) were bought and sold.

    • Regarding CERN (NASDAQ:CERN), we observe a call option trade with neutral sentiment. It expires in 260 day(s) on January 20, 2023. Parties traded 550 contract(s) at a $90.00 strike. The total cost received by the writing party (or parties) was $277.7K, with a price of $505.0 per contract. There were 9939 open contracts at this strike prior to today, and today 550 contract(s) were bought and sold.

    • For AXNX (NASDAQ:AXNX), we notice a put option sweep that happens to be bearish, expiring in 43 day(s) on June 17, 2022. This event was a transfer of 125 contract(s) at a $45.00 strike. This particular put needed to be split into 14 different trades to become filled. The total cost received by the writing party (or parties) was $25.8K, with a price of $205.0 per contract. There were 0 open contracts at this strike prior to today, and today 379 contract(s) were bought and sold.

    • For PFE (NYSE:PFE), we notice a call option trade that happens to be neutral, expiring in 260 day(s) on January 20, 2023. This event was a transfer of 125 contract(s) at a $50.00 strike. The total cost received by the writing party (or parties) was $46.8K, with a price of $375.0 per contract. There were 20261 open contracts at this strike prior to today, and today 360 contract(s) were bought and sold.

    • For UNH (NYSE:UNH), we notice a put option trade that happens to be neutral, expiring in 43 day(s) on June 17, 2022. This event was a transfer of 11 contract(s) at a $500.00 strike. The total cost received by the writing party (or parties) was $25.4K, with a price of $2310.0 per contract. There were 1146 open contracts at this strike prior to today, and today 313 contract(s) were bought and sold.

    • Regarding MRNA (NASDAQ:MRNA), we observe a put option sweep with bullish sentiment. It expires in 8 day(s) on May 13, 2022. Parties traded 94 contract(s) at a $143.00 strike. This particular put needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $71.4K, with a price of $760.0 per contract. There were 46 open contracts at this strike prior to today, and today 102 contract(s) were bought and sold.

    • For DOCS (NYSE:DOCS), we notice a put option trade that happens to be bullish, expiring in 225 day(s) on December 16, 2022. This event was a transfer of 21 contract(s) at a $45.00 strike. The total cost received by the writing party (or parties) was $30.4K, with a price of $1450.0 per contract. There were 683 open contracts at this strike prior to today, and today 69 contract(s) were bought and sold.

    • Regarding THC (NYSE:THC), we observe a put option trade with bullish sentiment. It expires in 43 day(s) on June 17, 2022. Parties traded 98 contract(s) at a $75.00 strike. The total cost received by the writing party (or parties) was $50.9K, with a price of $520.0 per contract. There were 206 open contracts at this strike prior to today, and today 40 contract(s) were bought and sold.

    • For SWAV (NASDAQ:SWAV), we notice a call option sweep that happens to be bearish, expiring in 15 day(s) on May 20, 2022. This event was a transfer of 30 contract(s) at a $150.00 strike. This particular call needed to be split into 8 different trades to become filled. The total cost received by the writing party (or parties) was $27.9K, with a price of $930.0 per contract. There were 207 open contracts at this strike prior to today, and today 38 contract(s) were bought and sold.

    • For CI (NYSE:CI), we notice a call option trade that happens to be bullish, expiring in 260 day(s) on January 20, 2023. This event was a transfer of 10 contract(s) at a $200.00 strike. The total cost received by the writing party (or parties) was $62.0K, with a price of $6200.0 per contract. There were 26149 open contracts at this strike prior to today, and today 36 contract(s) were bought and sold.

    Options Alert Terminology
    - Call Contracts: The right to buy shares as indicated in the contract.
    - Put Contracts: The right to sell shares as indicated in the contract.
    - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it.
    - Premium/Option Price: The price of the contract.

    For more information, visit our Guide to Understanding Options Alerts or read more about unusual options activity.

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AXNX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AXNX
    $CERN
    $CI
    $DOCS

    CompanyDatePrice TargetRatingAnalyst
    Pfizer Inc.
    $PFE
    3/2/2026$35.00Hold → Buy
    Argus
    Pfizer Inc.
    $PFE
    2/25/2026$25.00Underperform
    RBC Capital Mkts
    Pfizer Inc.
    $PFE
    2/20/2026$25.00Underweight
    Barclays
    Pfizer Inc.
    $PFE
    2/12/2026$27.00Outperform → Neutral
    Daiwa Securities
    Arcus Biosciences Inc.
    $RCUS
    2/12/2026$23.00Overweight → Equal Weight
    Wells Fargo
    Doximity Inc.
    $DOCS
    2/9/2026$34.00Hold → Buy
    Canaccord Genuity
    Doximity Inc.
    $DOCS
    2/6/2026$40.00Underweight → Neutral
    Analyst
    Moderna Inc.
    $MRNA
    1/28/2026$25.00Equal Weight
    Barclays
    More analyst ratings

    $AXNX
    $CERN
    $CI
    $DOCS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Arcus Biosciences Announces New Employment Inducement Grants

    Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced that the Compensation Committee of the Company's Board of Directors granted two new employees options to purchase a total of 17,050 shares of the Company's common stock at an exercise price per share of $23.43, which was the closing price on March 9, 2026, and restricted stock units to acquire a total of 8,550 shares of the Company's common stock. The equity awards were granted pursuant to the Company's 2020 Inducement Plan, which was approved by the Co

    3/9/26 4:35:00 PM ET
    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pfizer's Phase 2 Study of Trispecific Antibody Positive in Moderate to Severe Atopic Dermatitis

    Study met primary endpoint, demonstrating statistically significant increase in the percentage of participants achieving EASI-75 at Week 16 across all doses tested, compared to placebo Tilrekimig (PF-07275315) was well-tolerated with a favorable safety profile Tilrekimig has the potential to be a first-in-class, once-monthly trispecific antibody targeting interleukin-4 (IL-4), interleukin-13 (IL-13), and thymic stromal lymphopoietin (TSLP) for multiple chronic Type 2 (Th2) inflammatory conditions including atopic dermatitis, asthma, and chronic obstructive pulmonary disease (COPD) Based on encouraging results, Pfizer plans to accelerate tilrekimig to Phase 3 development, with a pi

    3/9/26 6:45:00 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AM Best Affirms Credit Ratings of The Cigna Group and Its Subsidiaries

    AM Best has affirmed the Financial Strength Rating (FSR) of A (Excellent) and the Long-Term Issuer Credit Ratings (Long-Term ICR) of "a+" (Excellent) of the key U.S. life/health subsidiaries and Europe-based insurance companies of The Cigna Group (Cigna) (headquartered in Bloomfield, CT) (NYSE:CI). The majority of Cigna's core U.S. health insurance entities are collectively referred to as Cigna Life & Health Group. In addition, AM Best has affirmed the Long-Term ICR of "bbb+" (Good) and the Long-Term Issue Credit Ratings (Long-Term IR) of Cigna. AM Best also has affirmed the Short-Term Issue Credit Rating (Short-Term IR) of Cigna. The outlook of these Credit Ratings (ratings) is stable. (

    3/4/26 5:40:00 PM ET
    $CI
    Medical Specialities
    Health Care

    $AXNX
    $CERN
    $CI
    $DOCS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Pfizer upgraded by Argus with a new price target

    Argus upgraded Pfizer from Hold to Buy and set a new price target of $35.00

    3/2/26 8:00:47 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RBC Capital Mkts initiated coverage on Pfizer with a new price target

    RBC Capital Mkts initiated coverage of Pfizer with a rating of Underperform and set a new price target of $25.00

    2/25/26 7:53:28 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays initiated coverage on Pfizer with a new price target

    Barclays initiated coverage of Pfizer with a rating of Underweight and set a new price target of $25.00

    2/20/26 8:25:15 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AXNX
    $CERN
    $CI
    $DOCS
    SEC Filings

    View All

    UnitedHealth Group Incorporated filed SEC Form 8-K: Regulation FD Disclosure

    8-K - UNITEDHEALTH GROUP INC (0000731766) (Filer)

    3/9/26 4:33:13 PM ET
    $UNH
    Medical Specialities
    Health Care

    SEC Form 144 filed by Tenet Healthcare Corporation

    144 - TENET HEALTHCARE CORP (0000070318) (Subject)

    3/9/26 1:08:26 PM ET
    $THC
    Hospital/Nursing Management
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by The Cigna Group

    SCHEDULE 13G/A - Cigna Group (0001739940) (Subject)

    3/5/26 1:24:31 PM ET
    $CI
    Medical Specialities
    Health Care

    $AXNX
    $CERN
    $CI
    $DOCS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chairman & CEO Cordani David bought $999,916 worth of shares (4,134 units at $241.88) (SEC Form 4)

    4 - Cigna Group (0001739940) (Issuer)

    11/3/25 2:47:56 PM ET
    $CI
    Medical Specialities
    Health Care

    President & CFO Rex John F bought $4,999,919 worth of shares (17,175 units at $291.12), increasing direct ownership by 9% to 203,796 units (SEC Form 4)

    4 - UNITEDHEALTH GROUP INC (0000731766) (Issuer)

    5/16/25 6:11:47 PM ET
    $UNH
    Medical Specialities
    Health Care

    CEO, UHG Hemsley Stephen J bought $25,019,019 worth of shares (86,700 units at $288.57), increasing direct ownership by 15% to 679,493 units (SEC Form 4)

    4 - UNITEDHEALTH GROUP INC (0000731766) (Issuer)

    5/16/25 6:11:45 PM ET
    $UNH
    Medical Specialities
    Health Care

    $AXNX
    $CERN
    $CI
    $DOCS
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    October 25, 2024 - FDA Roundup: October 25, 2024

    For Immediate Release: October 25, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA updated the advisory for the outbreak of E. coli O157:H7. A specific ingredient has not yet been confirmed as the source of the outbreak, but most sick people report eating McDonald’s Quarter Pounder burgers. Investigators are working to deter

    10/25/24 2:48:21 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for HYMPAVZI issued to PFIZER INC

    Submission status for PFIZER INC's drug HYMPAVZI (ORIG-1) with active ingredient MARSTACIMAB-HNCQ has changed to 'Approval' on 10/11/2024. Application Category: BLA, Application Number: 761369, Application Classification:

    10/15/24 2:57:27 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    October 11, 2024 - FDA Approves New Treatment for Hemophilia A or B

    For Immediate Release: October 11, 2024 Today, the U.S. Food and Drug Administration approved Hympavzi (marstacimab-hncq) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A without factor VIII inhibitors or hemophilia B without factor IX inhibitors (neutralizing antibodies). “Today’s approval of Hympavzi pro

    10/11/24 2:12:15 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AXNX
    $CERN
    $CI
    $DOCS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Tenet Healthcare Corporation

    4 - TENET HEALTHCARE CORP (0000070318) (Issuer)

    3/10/26 8:00:03 PM ET
    $THC
    Hospital/Nursing Management
    Health Care

    New insider Maloney Michael T. claimed ownership of 101,990 shares (SEC Form 3)

    3 - TENET HEALTHCARE CORP (0000070318) (Issuer)

    3/9/26 8:00:04 PM ET
    $THC
    Hospital/Nursing Management
    Health Care

    Chief Legal Officer Klinger Shannon Thyme covered exercise/tax liability with 5,704 shares and converted options into 11,797 shares, increasing direct ownership by 10% to 65,782 units (SEC Form 4)

    4 - Moderna, Inc. (0001682852) (Issuer)

    3/6/26 4:24:57 PM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AXNX
    $CERN
    $CI
    $DOCS
    Leadership Updates

    Live Leadership Updates

    View All

    ParaZero Strengthens Global Sales Leadership with Appointment of Bat-Sheva Noy as VP

    Kfar Saba, Israel, March 04, 2026 (GLOBE NEWSWIRE) -- ParaZero Technologies Ltd. (NASDAQ:PRZO) (the "company" or "ParaZero"), an aerospace defense company pioneering smart, autonomous solutions for the global manned and unmanned aerial systems (UAS) industry, recently announced the appointment of Bat-Sheva Noy as its new Vice President of Global Sales. Ms. Noy brings more than 20 years of extensive commercial and leadership experience, with particular expertise in strategic planning, market access, and leading cross-functional teams. Most recently, from 2020 to 2025, she served as the Business Unit Lead for Rare Diseases at Pfizer Israel ((a subsidiary of Pfizer Inc., NYSE:PFE). In that

    3/4/26 8:32:00 AM ET
    $PFE
    $PRZO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Military/Government/Technical
    Industrials

    The Cigna Group Announces President & COO Brian Evanko to Succeed David M. Cordani as Chief Executive Officer

    Cordani to retire as chief executive officer on July 1, 2026, and will serve as executive chair of The Cigna Group Board of DirectorsEvanko elected to the company's Board of DirectorsCompany reaffirms 2026 Financial OutlookBLOOMFIELD, Conn., March 3, 2026 /PRNewswire/ -- The Cigna Group (NYSE: CI) today announced that David M. Cordani will retire as chief executive officer effective July 1, 2026, and become executive chair of The Cigna Group's Board of Directors. Brian Evanko, current president and chief operating officer, will succeed Cordani as CEO. Throughout his tenure—inclu

    3/3/26 7:30:00 AM ET
    $CI
    Medical Specialities
    Health Care

    Tectonic Therapeutic Appoints François Nader, M.D., as Chair and Independent Director of the Board

    WATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) ("Tectonic"), a clinical-stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced it has appointed François Nader, M.D., MBA, as an independent director to its Board of Directors, effective April 1, 2026, at which time he will also assume the role of Chair of the Board. Dr. Nader brings more than 30 years of leadership experience across the biotechnology and pharmaceutical industry and currently serves as an Independent Director of Moderna, Inc. (NASDAQ:MRNA), a glo

    2/23/26 4:01:00 PM ET
    $MRNA
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AXNX
    $CERN
    $CI
    $DOCS
    Financials

    Live finance-specific insights

    View All

    AM Best Affirms Credit Ratings of The Cigna Group and Its Subsidiaries

    AM Best has affirmed the Financial Strength Rating (FSR) of A (Excellent) and the Long-Term Issuer Credit Ratings (Long-Term ICR) of "a+" (Excellent) of the key U.S. life/health subsidiaries and Europe-based insurance companies of The Cigna Group (Cigna) (headquartered in Bloomfield, CT) (NYSE:CI). The majority of Cigna's core U.S. health insurance entities are collectively referred to as Cigna Life & Health Group. In addition, AM Best has affirmed the Long-Term ICR of "bbb+" (Good) and the Long-Term Issue Credit Ratings (Long-Term IR) of Cigna. AM Best also has affirmed the Short-Term Issue Credit Rating (Short-Term IR) of Cigna. The outlook of these Credit Ratings (ratings) is stable. (

    3/4/26 5:40:00 PM ET
    $CI
    Medical Specialities
    Health Care

    Arcus Biosciences Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides a Pipeline Update

    Updated data for casdatifan in late-line kidney cancer demonstrated median progression-free survival (PFS) of 15.1 months and a confirmed overall response rate (cORR) of 45% for the 100mg once-daily (QD) cohort At least two additional data presentations for casdatifan are expected in 2026: updated data for casdatifan plus cabozantinib and initial data in early-line kidney cancer In addition to the ongoing Phase 3 PEAK-1 study, Arcus plans to initiate a Phase 3 study in the first-line (1L) metastatic setting evaluating casdatifan in a tyrosine kinase inhibitor (TKI)-free combination by the end of 2026 With $1.0 billion in cash, cash equivalents and marketable securities at year-

    2/25/26 4:05:00 PM ET
    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    UnitedHealth Group Board Authorizes Payment of Quarterly Dividend

    The UnitedHealth Group (NYSE:UNH) board of directors has authorized payment of a cash dividend of $2.21 per share, to be paid on March 17, 2026, to all shareholders of record of UNH common stock as of the close of business March 9, 2026. About UnitedHealth Group UnitedHealth Group (NYSE:UNH) is a health care and well-being company with a mission to help people live healthier lives and help make the health system work better for everyone through two distinct and complementary businesses. Optum delivers care aided by technology and data, empowering people, partners and providers with the guidance and tools they need to achieve better health. UnitedHealthcare offers a full range of health

    2/25/26 6:50:00 AM ET
    $UNH
    Medical Specialities
    Health Care

    $AXNX
    $CERN
    $CI
    $DOCS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Arcus Biosciences Inc.

    SC 13D/A - Arcus Biosciences, Inc. (0001724521) (Subject)

    12/17/24 9:52:58 PM ET
    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Doximity Inc.

    SC 13G/A - Doximity, Inc. (0001516513) (Subject)

    11/14/24 5:22:01 PM ET
    $DOCS
    EDP Services
    Technology

    Amendment: SEC Form SC 13G/A filed by Tenet Healthcare Corporation

    SC 13G/A - TENET HEALTHCARE CORP (0000070318) (Subject)

    11/14/24 4:17:18 PM ET
    $THC
    Hospital/Nursing Management
    Health Care